Nasdaq Ctmx News Today

BMO Capital Markets restated their market perform rating on shares of CytomX Therapeutics (NASDAQ:CTMX – Free Report) in a report published on Wednesday, Benzinga reports. BMO Capital Markets currently has a $3.25 target price on the biotechnology company’s stock. A number of other equities research analysts have also commented on CTMX. StockNews.com lowered CytomX Therapeutics […]

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase...

CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) was the recipient of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 1,250,000 shares, a decline of 5.3% from the January 15th total of 1,320,000 shares. Based on an average daily trading volume, of 294,600 […]

CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 981,600 shares, a decline of 26.7% from the November 30th total of 1,340,000 shares. Based on an average daily trading volume, of 197,200 […]

CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) CEO Sean A. Mccarthy sold 13,551 shares of the business’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $1.38, for a total value of $18,700.38. Following the completion of the sale, the chief executive officer now […]

CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report)’s share price crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $1.26 and traded as low as $1.22. CytomX Therapeutics shares last traded at $1.29, with a volume of 98,346 shares. Wall Street Analyst Weigh […]

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 - - CX-2051 (EpCAM-directed ADC)...

CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Tuesday, November 7th. Analysts expect CytomX Therapeutics to post earnings of ($0.17) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link. CytomX […]

- CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor...

CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Rating) has been assigned an average recommendation of “Hold” from the twelve ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and three have given a buy recommendation to the company. […]